# Phase 4 carcinoma trials recruiting: 49 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials in phase 4 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 carcinoma trials: 49 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 49
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07910474 | FES PET/MRI for Occult Disease in Lobular Breast Cancer | University of Wisconsin, Madison | Phase 4 | Recruiting | Lobular Breast Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910474) |
| October 13, 2026 | NCT07872553 | A Study of Treatment Delivery Preference In People With Kidney Cancer | Memorial Sloan Kettering Cancer Center | Phase 4 | Recruiting | Renal Cell Carcinoma, Kidney Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872553) |
| September 16, 2026 | NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | Eli Lilly and Company | Phase 4 | Not yet recruiting | Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822880) |
| August 10, 2026 | NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754812) |
| August 4, 2026 | NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) | Anhui Provincial Cancer Hospital | Phase 4 | Recruiting | Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744698) |
| July 22, 2026 | NCT07720726 | Impact of Dysport on PMFF Donor Scar | Vanderbilt University Medical Center | Phase 4 | Not yet recruiting | Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720726) |
| July 15, 2026 | NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Phase 4 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704658) |
| June 25, 2026 | NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | Hebei Medical University Fourth Hospital | Phase 4 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668570) |
| June 8, 2026 | NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of... | Centre Antoine Lacassagne | Phase 4 | Not yet recruiting | Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633613) |
| March 20, 2026 | NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage... | The Affiliated Hospital of Qingdao University | Phase 4 | Not yet recruiting | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485920) |
| March 13, 2026 | NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced... | Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor... | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469488) |
| February 12, 2026 | NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | OHSU Knight Cancer Institute | Phase 4 | Recruiting | Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405086) |
| January 22, 2026 | NCT07358975 | Prediction of Complications in Hepatic Tumors | Copenhagen University Hospital, Rigshospitalet | Phase 4 | Not yet recruiting | Hepatic Tumors | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358975) |
| January 6, 2026 | NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | Fujian Cancer Hospital | Phase 4 | Recruiting | Non-Small Cell Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07320105) |
| December 12, 2025 | NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA... | AstraZeneca | Phase 4 | Recruiting | Non-small Cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279935) |
| September 8, 2025 | NCT07160361 | Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB | Second Affiliated Hospital of Xi'an Jiaotong University | Phase 4 | Not yet recruiting | Carcinoma, Hepatocellular | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07160361) |
| September 2, 2025 | NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | Anhui Provincial Hospital | Phase 4 | Recruiting | Hepatocellular Carcinoma (HCC), Liver Diseases | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07150624) |
| August 20, 2025 | NCT07132515 | Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC | Mansoura University | Phase 4 | Recruiting | Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07132515) |
| July 10, 2025 | NCT07059494 | Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | Icahn School of Medicine at Mount Sinai | Phase 4 | Recruiting | Hepatocellular Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059494) |
| June 19, 2025 | NCT07028125 | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma | Centre Francois Baclesse | Phase 4 | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07028125) |
| June 11, 2025 | NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | Beijing GoBroad Hospital | Phase 4 | Not yet recruiting | Neuroendocrine Carcinomas (NEC) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07014540) |
| April 30, 2025 | NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune... | China Medical University, China | Phase 4 | Not yet recruiting | Small Cell Lung Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06951841) |
| April 18, 2025 | NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 | Recruiting | Kidney Cancer, Renal Cell Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06934057) |
| April 17, 2025 | NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | Peking Union Medical College Hospital | Phase 4 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06931145) |
| April 11, 2025 | NCT06923176 | Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 704 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06923176) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shanghai Pulmonary Hospital, Shanghai, China | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| University of Texas Southwestern Medical Center | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Peking Union Medical College Hospital | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Third Affiliated Hospital, Sun Yat-Sen University | 1 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 1 |
| Maastricht University Medical Center | 1 |
| Samsung Medical Center | 1 |
| Hong Kong Children's Hospital | 1 |
| Vanderbilt University Medical Center | 1 |
| Fujian Cancer Hospital | 1 |
| Sun Yat-sen University | 1 |
| Fudan University | 1 |
| Beijing GoBroad Hospital | 1 |
| Anhui Provincial Cancer Hospital | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| University Medical Center Groningen | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Shanghai Chest Hospital | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| University of Wisconsin, Madison | 1 |
| The Affiliated Hospital of Qingdao University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 14 |
| United States | 9 |
| France | 7 |
| Netherlands | 5 |
| Spain | 4 |
| Italy | 3 |
| Denmark | 3 |
| Germany | 3 |
| India | 2 |
| South Korea | 2 |
| Austria | 2 |
| Czechia | 2 |
| Canada | 2 |
| Russia | 2 |
| Taiwan | 2 |
| Hong Kong | 1 |
| Belgium | 1 |
| Lithuania | 1 |
| Norway | 1 |
| Poland | 1 |
| Portugal | 1 |
| Sweden | 1 |
| Switzerland | 1 |
| United Kingdom | 1 |
| Brazil | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
